JonesTrading Initiates Coverage On Acrivon Therapeutics with Buy Rating, Announces Price Target of $26
Portfolio Pulse from richadhand@benzinga.com
JonesTrading analyst Soumit Roy has initiated coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and a price target of $26.
August 18, 2023 | 9:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics has been given a Buy rating by JonesTrading with a price target of $26.
The Buy rating and price target set by JonesTrading analyst Soumit Roy indicates a positive outlook for Acrivon Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100